Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

- 1 Title: Healthcare seeking behavior and delays in case of drug-resistant Tuberculosis
- 2 patients in Bangladesh: Findings from a cross-sectional survey

3 Authors

- 4 **1.** Md. Zulqarnine Ibne Noman^{1,2}
- 5 2. Shariful Islam²
- 6 3. Shaki Akter^{1,3}
- 7 4. Ateeb Ahmad Parray ^{1,5*}
- 8 5. Dennis G Amando¹
- 9 6. Jyoti Karki¹
- 10 7. Zafria Atsna¹
- 11 8. Dipak Mitra 4
- 12 9. Shaikh A. Shahed Hossain¹

13 Affiliation

- 14 **1.** BRAC James P. Grant School of Public Health (JPGSPH), BRAC university, Dhaka-
- 15 1212, Bangladesh
- 16 **2.** EcoHealth Alliance Bangladesh Programs, Institute of Epidemiology, Disease
- 17 Control and Research (IEDCR), Dhaka 1212, Bangladesh
- **3.** International Centre for Diarrhoeal Disease Research (icddr,b), Bangladesh, Dhaka,
- 19 Bangladesh
- 20 **4.** Department of Public Health, North South University, Dhaka, Bangladesh
- 21 5. Department of International Health, Health systems program, The Johns Hopkins
- 22 University, Baltimore, USA NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

23 *Corresponding Author

- 24 Email ahmad.ateeb101@gmail.com
- 25 Keywords Care seeking, drug-resistant Tuberculosis, Patient delay, Diagnostic delay,
- 26 Treatment delay, Total delay, Bangladesh

27 Acknowledgements

28 The study was conducted under Summative Learning Project (SLP), as a partial requirement 29 of MPH degree at BRAC James P Grant School of Public Health, BRAC University. This work 30 has been funded by collectively by BRAC James P Grant School of Public Health, BRAC University and TDR under grant number: B40297, the Special Programme for Research and 31 32 Training in Tropical Diseases, which is hosted at the World Health Organization and cosponsored by UNICEF, UNDP, the World Bank and WHO. We are also indebted towards Dr. 33 Aung, Country director, Damien foundation and Dr. Abdul Hamid Selim, Sr. Scientist, 34 35 National Tuberculosis and Leprosy control Programme, Ministry of Health and family 36 welfare, Govt. of People's Republic of Bangladesh for their full-on cooperation during the timeframe of the study. 37

38 **Competing Interests**

39 The authors have declared no competing interests.

40 **Conflict of Interests**

41 The authors have declared no conflict of interests.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

43 Abstract

Background: The emergence of Drug-Resistant Tuberculosis (DR-TB) has become a major
threat globally and Bangladesh is no exception. Delays in healthcare seeking, proper
diagnosis and initiation of treatment cause continuous transmission of the resistant
tubercule bacilli through the communities. This study aimed to assess the different health
care-seeking behaviors and delays among DR-TB patients in Bangladesh.

Method: A prospective cross-sectional study was conducted from November to December
2018, among 92 culture positive and registered DR-TB patients in four selected hospitals in
Bangladesh. Data were collected through face-to-face interviews with survey questionnaire
as well as record reviews.

Result: Among the 92 study participants, the median patient delay was 7 (IQR 3, 15) days, the median diagnostic delay was 88 (IQR 36.5, 210), the median treatment delay was 7 (IQR 4,12) days, and the median total delay among DR-TB patients was 108.5 (IQR 57.5, 238) days. 81.32% sought initial care from informal healthcare providers. The majority (68.48%) of the informal healthcare providers were drug sellers while 60.87% of patients sought care from more than four healthcare points before being diagnosed with DR-TB. The initial care seeking from multiple providers was associated with diagnostic and total delays.

60 **Conclusion:** In Bangladesh, DR-TB cases usually seek care from multiple providers, 61 particularly from informal providers, and among them, alarmingly higher healthcare-seeking 62 related delays were noted. Immediate measures should be taken both at the health system 63 levels and, in the community, to curb transmission and reduce the burden of the disease.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

65 Introduction

66	Tuberculosis (TB) is a highly transmissible disease caused by Mycobacterium tuberculosis
67	bacilli, the second most infectious killer after the COVID-19 pandemic and the 13 th leading
68	cause of overall mortality around the world (1). It is estimated that about a quarter of the
69	world's population is already infected with TB though only 10% of them develop clinical TB
70	during their lifetime (1) (2). The END TB-2030 strategy was developed with a vision of
71	reducing the number of TB death by 90% and reduction of new cases by 80% (3). However,
72	the emergence of drug-resistant tuberculosis (DR-TB) has become a global threat and
73	challenges the End TB-2030 strategy as only one of four new DR-TB cases are now detected
74	while one of two cases got cured (3).

DR-TB is a clinical condition where any of the first-line anti-TB drugs is found resistant. It can be categorized as single-drug-resistant, multi-drug-resistant, or extensive drug-resistant (4). Multi-drug resistant tuberculosis (MDR-TB) is the most common form of DR-TB which is resistant to first-line anti-TB drugs Rifampicin (RFP) and Isoniazid (INR). When one fluoroquinolone and a second-line injectable drug are also resistant, then it is categorized as extensive/extreme drug-resistant tuberculosis (XDR-TB) also known as super-bugs, which may facilitate a global tubercular apocalypse, if not prevented, and intervened timely (5) (6).

About 157 thousand incident cases of DR-TB were notified, and 150 thousand new cases were enrolled in treatment in 2020 according to the Global TB report. However, the estimated number of new cases of DR-TB is 500 thousand each year while only one of the three cases was treated (7). There was a 22% fall in new case detection and a 15% fall in new enrollment in DR-TB treatment from 2019 due to the COVID-19 pandemic. However, only one of three newly developed DR-TB cases each year are enrolled for treatment (1). The undiagnosed, late diagnosed, and lately treated cases cause the continuous spreading of resistant bacilli in

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

the community(8). The high risk of transmission, high case fatality, prolonged treatment,
financial, and social burden make DR-TB control strategy more complicated for low and
middle socio-income countries like Bangladesh (9). Bangladesh is one of the leading TB
burden countries among the top 30 countries (10). In 2020, the laboratory-confirmed number
of new DR-TB cases in Bangladesh was 1113, and the incidence rate of DR TB was 2%
according to the Global TB report 2020(9).

Early diagnosis of DR-TB and timely initiation of treatment are important. Any delays in the 95 96 initiation of treatment cause more complications, more disease transmission, and higher 97 mortality. An untreated smear-positive TB case can infect 10 more patients in a year and more than 20 patients during its natural course until death (11). Healthcare-seeking behavior 98 is an influential factor in the diagnosis and prognosis of MDR-TB (12). Patient delays and 99 diagnostic delays depend on patterns of care-seeking of a patient. In South Asia, patients 100 usually visit informal healthcare providers as the first point of care (13). Drug sellers, 101 102 traditional healers, village doctors, ayurvedic, and homeopaths are recognized as informal healthcare providers in Bangladesh(14). About 60.7% of Bangladeshi patients usually seek 103 first care from pharmacies or traditional providers(15). The number of care-seeking points is 104 usually more as the patients shift from one provider to another until the final diagnosis from 105 the DOTS center which is the diagnostic point of DR-TB. The number of Care seeking points 106 have a greater influence on delay among patients (16). Moreover, among the healthcare 107 providers, the likelihood of initial suspicion about the diagnosis of TB was found low (17). 108 Additionally, social stigma, fear of isolation, and misbelief also cause delays in care-seeking 109 and causes patient delays(18). Gender, education, geography, and socio-economic condition 110 are some contributing factors that determine the care-seeking behavior of DR-TB in sub-111 Saharan Africa(19). 112

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

113 A study in India found a median patient delay of 25 days for uncomplicated pulmonary TB 114 patients (20). In Bangladesh, the median health system delay was found 7.1 weeks and the 115 median treatment initiation delay was found 10 days among MDR-TB patients in a previous study conducted in 2012-2013 (21). WHO recommends no more than 1-day delay for 116 screening to diagnosis and diagnosis to treatment initiation Policy on TB infection control 117 (22). Few authors suggested that a one-month total delay is acceptable while others 118 suggested the total delay should not exceed two months (23). However, very few studies 119 assessed the possible factors related to healthcare-seeking behavior and different delays of 120 DR-TB patients as a whole and particularly from Bangladesh. 121

The aim of this study was to assess healthcare-seeking behaviors and delays of drugresistance tuberculosis patients. The evidence from this study will be useful for TB control program to take different specific measure at all levels of health systems and in the community level as necessary, to reduce different delays and to implement the END TB strategy by 2030 successfully.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

128 Methods

129 Setting and Study population

We conducted a prospective cross-sectional study, country wide, to reach the objectives. A 130 131 quantitative survey design was adopted using the prospective cross-sectional approach. In Bangladesh, there are 46 chest clinics, one 250-bedded dedicated TB hospital, several 132 medical college hospitals, and one specialized chest disease hospital for treating TB. We 133 purposefully selected four centers where the flow of TB and DR-TB cases were the most 134 among all centers (24). This study was conducted at the National Institute of Diseases of 135 Chest and Hospital (NIDCH), Dhaka; Mymensingh Tuberculosis and Leprosy hospital; 136 Netrakona Tuberculosis and Leprosy hospital; and Tangail Tuberculosis and Leprosy hospital 137 (Figure-1). A few DR-TB patients (13) were interviewed in nearby Upazilla health complexes 138 (UHC) and adjoining communities of respective catchment areas of enrolled TB hospitals in 139 Netrakona and Tangail also to reach the estimated sample size of 92. The patients from the 140 community were identified from the MDR-TB register of the International Non-141 142 governmental organization (INGO) - Damien Foundation (DF), as they were under treatment from DF. The NIDCH is the tertiary public hospital in Mohakhali, Dhaka. This is the top 143 referral hospital for DR-TB in Bangladesh. There are 685 beds while 70 beds are reserved for 144 DR-TB patients(25). GF works in 17 countries in Asia. In Bangladesh, they are working in the 145 field of leprosy and TB in collaboration with the National Tuberculosis Control Program 146 147 (NTP) of Bangladesh. They have three referral hospitals for MDR-TB treatment. This study 148 was conducted in all three referral TB hospitals managed by the DF, which comprises of total 255 beds in Tangail (95 beds), Mymensingh (100 beds), and Netrakona (60 beds) (26). 149

150 Figure 1: Map of study site locations presenting the distribution of different delays among
151 DR-TB patients in Bangladesh

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

From 17th November to 7th December 2018, all DR-TB patients admitted to the four selected TB hospitals and community patients available from the near the catchment areas of TB hospitals in Tangail and Netrakona during the time of the survey were considered as the study population. Patients with DR-TB were bacteriologically confirmed, either by GeneXpert or culture. The study comprised patients aged 16 or older who were registered with NTP. All forms of DR-TB treatment registration groups were covered. Patients with severe illnesses were excluded from our study.

A total of 41 patients were from NIDCH, 23 from Mymensingh TB hospital, 9 from Tangail,

and 6 from Netrakona TB hospital. Moreover, 13 available DR-TB patients were interviewed

161 from the catchment areas of Netrakona and Tangail TB hospitals.

162 Study tools and data collection

A pretested structured survey questionnaire was used to conduct face-to-face interviews. 163 The health care seeking questionnaire was adopted from the WHO document "*Diagnostic* 164 and treatment delay in tuberculosis- An in-depth analysis of the health-seeking behavior of 165 166 patients and health system response in seven countries of the Eastern Mediterranean *Region*"(27). The questionnaire was translated into the local language Bangla and then again 167 back translated into English to check the accuracy and consistency of the tool. The 168 questionnaire was modified according to the pretesting experiences as per the consensus of 169 the research team. Hospital records were reviewed from the DR-TB card, Sputum register, 170 TB register and Laboratory log to source match the credentials of the hospital admitted 171 study participants as well as participants from catchment areas. Two researchers and three 172 trained research assistants with medical backgrounds who were good in the local language 173 conducted all the interviews. After interviewing each DR-TB patient, the TB-card was 174 reviewed for validation of patient information and for some key information like treatment 175

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

176 registration group, date of diagnosis and date of treatment, etc. Any conflict between

177 patient response and data records, record data was preferred to reduce recall bias.

178 Operational definitions

Resistance against one or more anti-TB drugs was considered as DR-TB. It can be single-drug 179 resistant, multi-drug resistant, or extensive drug-resistant. Resistance against the first-line 180 anti-TB drug, Rifampicin (RFP) and Isoniazid (INR) was considered as MDR-TB. The patients 181 who had never been treated for TB before were categorized as new MDR-TB. The patients 182 who were previously treated for TB and were declared as cured were considered as relapse-183 MDR-TB. The patients who were previously treated for TB but could not complete or lost to 184 follow up (LTFU) were categorized as re-treatment MDR-TB. When a patient previously 185 received TB treatment but the outcome of the treatment was unknown or undocumented, 186 known as other-MDR-TB (24). Resistant against first-line anti-TB drugs with the resistance 187 of one fluoroquinolone and a second-line injectable drug (aminoglycosides and 188 capreomycin) was categorized as XDR-TB. The participants were asked about the date of the 189 190 onset of the first symptom regarding TB, the date of the first care-seeking from any providers, the date of diagnosis, and the date of treatment initiation. Patient delay was 191 considered as the time between the onset of symptoms of TB identified by a patient to the 192 first care-seeking from any healthcare provider (20). The time between first care-seeking by 193 a patient and being confirmed diagnosed with DR-TB by GeneXpert/Culture was considered 194 as Diagnostic delay (28). Treatment delay was defined as the time between a patient 195 diagnosed with DR-TB and initiation of DR-TB treatment by healthcare providers(27). The 196 time between a patient first recognizing his/her symptoms of DR-TB and getting initiation of 197 treatment was calculated as total delay (20) (Fig. 2). Delay more than the median value 198 considered as long delay. 199

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

Figure 2: Definition of different delays (27) (28).

According to the NTP guideline of Bangladesh, all DR-TB patients are leveled with the 201 different treatment registration groups- new cases, relapse cases, failure of treatment by 1st 202 line drug (F1), failure of treatment by 1st line drug due to loss to follow-up, failure of 203 retreatment by 1st line drugs (F2), other cases and XDR-TB. New cases were labeled as those 204 205 who had no previous history of TB. Relapse cases are those who had a history of TB, but 206 treatment was completed and cured. Other cases were labeled who had a history of TB but no documents of taking or completement of drugs. Doctors, both public and private and 207 DOTS providers are defined as formal healthcare providers in this study. Drug sellers, Village 208 doctors (LMF), Traditional healers, Homeopaths, and Ayurvedic were defined as informal 209 healthcare providers. Self-care at home was also categorized as informal care. 210

211 Data analysis

All data were entered and cleaned through MS excel (Microsoft Office Professional Plus 212 2021, Microsoft Corporation, Washington, United States) and analyzed through STATA 213 version 16.0 (StataCorp, 4905, Lakeway Drive, College Station, Texas 77, 845, USA). 214 Descriptive analysis of Socio-demographic characteristics, clinical and personal profile was 215 done using frequency and percentages. Delays were measured using median and range. We 216 performed univariable logistic regression analysis for all predictive factors for different 217 delays and odds ratios (ORs), and 95 % confidence intervals (CI) were calculated. Patient 218 delay was calculated from patient recall. Diagnostic delay was calculated by subtracting 219 220 patient delay from the date of diagnosis collected from the TB card. Treatment delay was calculated by subtracting the date of diagnosis from the date of treatment initiation 221 collected from the hospital records. 222

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

223 Ethical approval

Ethical approval was obtained from the institutional review board (IRB) of James P. Grants 224 School of Public Health, BRAC University under reference number 2018-40-IR. Formal 225 permission was also taken from the head office of Damien Foundation Bangladesh and 226 respective hospital management. Informed written consent was ensured for all respondents 227 228 over eighteen years after verbal explanation about the study. Informed written consent was 229 taken from parents and assent was taken from respondents under eighteen years of age. Thumbprint was taken, those who were illiterate. The anonymity and confidentiality of all 230 respondents were well-maintained. Personal protective equipment (PPE) including No5 231 masks was used while interviewing. For community patients, interviews were taken from the 232 nearest directly observed treatment, short-course (DOTS) centers. Transport costs were 233 234 provided to the community participants.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

236 Result

237	Among the total of 92 patients interviewed, 25 (27.17%) were new MDR-TB, 29 (31.52%) were
238	Relapse-MDR-TB, 33 (35.87%) were Re-treatment-MDR-TB, 3 (3.26%) were XDR-TB and 2
239	(2.17%) were other MDR-TB patients. Among the participants, 69 (75%) were men, 45
240	(48.91%) patients were 16-34 years of age and most of them 66 (71.74%) were living in rural
241	areas. Most participants were married 76 (82.61%) and engaged in manual work 40 (43.48%).
242	Most of the patients 42 (45.65%) had never attended school. The majority were previously
243	smokers 47 (51.09%) while 15 (16.30%) were found current smokers. The larger portion of the
244	participants 38 (41.30%) had a family income range between 10001-20000 BDT.
245	Very few of them were alcoholics 6 (6.52%) while 16 (17.39%) had diabetes and 10 (10.87%)
246	had other co-morbid diseases. The history of the previous TB infection was present among
247	62 (67.39%) patients while 60 (65.22%) had BCG scar proving they were vaccinated.
248	The most common symptoms presented by the patients at the time of first care-seeking
249	from any healthcare provider were Fever 83 (90.22%) and Cough 78 (84.87%). Other major
250	symptoms were weight loss 61 (66.30%), Haemoptysis 12 (13.04%), Chest pain 23 (25%) and
251	anorexia 10 (10.87%). Three or less symptoms were initially present among most of the 67
252	(72.83%) patients. The first healthcare provider, they consulted with was an informal
253	provider in most cases 74 (81.32%). The majority of patients 56 (60.87%) sought care from
254	more than four care-seeking points before getting a confirmatory diagnosis (Table-1).

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

Table 1: Frequency distribution with sociodemographic factors, clinical symptoms, care

257 seeking variables

Characteristics	Number of patients (%)
Sex	
Men Women	69 (75) 23 (25)
Age (year)	25 (25)
16-34	45 (48.91)
35-54	23 (25.00)
<u>≥55</u>	24 (26.09)
Residence Rural	66 (71.74)
Urban	22 (23.91)
Semi-urban	04 (4.35)
Marital Status	
Ever married	76 (82.61)
Never married Employment	16 (17.39)
Unemployed	9 (9.78)
Sales & service	16 (17.39)
Business	10 (10.87)
Manual work	40 (43.48)
Housewife Other	9 (9.78) 8 (8.70)
Educational status	0 (0.70)
Not attended school	42 (45.65)
Primary	19 (20.65)
Secondary & above	31 (33.70)
Current smoker Yes	15 (16.30)
No	77 (83.70)
Past smoker	((05.10)
Yes	47 (51.09)
No	45 (48.91)
Family income (BDT)	22 (24 78)
≤10000 10001-20000	32 (34.78) 38 (41.30)
≥20000	22 (23.91)
Consume alcohol	
Yes	6 (6.52)
No DM	86 (93.48)
Yes	16 (17.39)
No	76 (82.61)
BCG scar	
Yes	60 (65.22)
No Don't know	21 (22.83) 11 (11.96)
History of the previous TB	11 (11.90)
Yes	62 (67.39)
No	30 (32.61)
Number of care-seeking points	52 (57 (1))
≤5 >5	53 (57.61) 39 (42.39)
Co-morbid disease	57 (42.57)
Yes	10 (10.87)
No	82 (89.13)
Treatment registration group	25 (25.15)
New, MDR Relapse, MDR	25 (27.17) 29 (31.52)
Re-treatment, MDR	33 (35.87)
Other, MDR	2 (2.17)
X-DR	3 (3.26)
Symptoms	
Fever	83 (90.22)
Cough	78 (84.78)
Weight loss	61 (66.30)
Chest pain	23 (25.00)
Hemoptysis	12 (13.04)

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

Anorexia	10 (10.87)
Other	04 (4.35)
Number of initial symptoms	
≤3	67 (72.83)
>3	25 (27.17)
Type of first healthcare provider	
Formal	17 (18.68)
Informal	74 (81.32)
Number of care-seeking points	
_≤4	36 (39.13)
>4	56 (60.87)

The median patient delay was found 7 (IQR 3,15) days. The median diagnostic delay was 88 (IQR 36.5, 210) days and the median treatment delay was 7 (IQR 4,12) days, while the total delay was 108.5 (IQR 57.5, 238) days. Before getting the diagnosis, the median number of care-seeking points was 5 (IQR 4,6) (Figure 2). The mean patient delay was 15.38 days. The mean diagnostic delay was 123.46 days, the mean treatment delay was 9.63 days, while the mean total delay was 148 days.

264 **Figure 3:** Median and IQR of Different delays among DR-TB patients in Bangladesh

Half of the (54.35%) DR-TB patients had more total delay while patients in NIDCH (63.41%)

and Netrakona (62.50%) had the most. Most of the participants from Netrakona had more

patients delay (50.00%), diagnostic delay (75.00%) and Treatment delay (62.50%) (Map-1,

268 table-2).

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

270 Table 2: Percentage of DR-TB patients who had long delays according to the study sites*

Long delays	NIDCH (%) n= 41	Mymensingh (%) n= 23	Tangail (%) n = 20	Netrakona (%) n = 8	Overall (%) n = 92
Patient delay	39.02	47.83	20.00	50.00	38.04
Diagnostic delay	65.85	47.83	50.00	75.00	52.17
Treatment delay	56.10	56.52	25.00	62.50	50.00
Total delay	63.41	47.83	40.00	62.50	54.35

271 * The table shows the percentages of DR-TB patients who had long patients, diagnostic,

treatment, and total delay according to the study sites. Patient delay > 7 days, diagnostic delay

273 > 88 days, treatment delay > 7 days, and total delay > 108 days are considered as long delay.

274 The median patient delay varied in sex, age, marital status, occupation, monthly family 275 income, and presence of co-morbid diseases. Men had nearly double the median patient delay of 14 (IQR 3, 25) days than females 6 (IQR 3, 10) days. The young adult group of age (16-276 34 years) had more patient delay 7 (IQR 3,15) days than the older age group 35-54 years of 277 age (6.5 days) and \geq 55 years of age (5.5 days). The ever-married patients had a more median 278 patient delay of 7 (IQR 3,15) days than the never-married group of 5 (3-14.5) days. 279 280 Unemployed persons had a median patient delay of 14 (IQR 3,15) days than other 281 professionals such as manual workers, housewives, and businessmen. The person whose occupation was "Sales & Service", had a less median patient delay of 3.5 (IQR 3,7.5) days. The 282 median patient delay was 4 (IQR 3,7) days among patients who had monthly family income 283 ≥20,000 BDT while those who had monthly family income <20,000 BDT, had a patient delay 284 of 7 (IQR 3,15) days. The patients who had comorbid diseases found less patient delay 4.5 285 286 (IQR 3,7) days while others had 7 (IQR 3,15) days (Table 3).

The median diagnostic delay was found more among men 102 (IQR 33,180) days than women 87 (IQR 39,224) days. Young adults (18-34 years of age) had more median diagnostic delay of 101.5 (IQR 36, 201) days than other age groups. Urban patients had less median diagnostic

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

290 delay of 60 (IQR 31, 129) days than rural patients 90 (37, 226) days. Patients who never 291 married found more median diagnostic delay 125 (IQR 23.5, 211.5) days than ever married 84 292 (IQR 42, 206.5) days. Housewives had more median diagnostic delay 106 (IQR 62,142) days than other professions. Higher educated patients had a less diagnostic delay. Educated up to 293 secondary and higher levels had a median diagnostic delay of 81 (IQR 36, 180) days. Current 294 smokers had more delays 125 (IQR 60, 237) days than non-smokers 84 (IQR 36,194) days. 295 Lower-income patients had a median diagnostic delay of 103 (IQR 56, 226) which was more 296 297 than higher-income patients. Diabetic patients had less diagnostic delay 32 (IQR 23, 64) days than non-diabetic 98 (IQR 60, 222) days. The patient with a previous TB infection had a 298 median diagnostic delay of 105 (IQR 62, 231) days which was more than those who didn't 299 have pre-TB 39 (IQR 24, 89) days. The median diagnostic delay of 142 (IQR 72, 237) days was 300 301 found among those who had number of care-seeking points more than 5 and 62 (IQR 30, 134) days who had the number of care-seeking points ≤5. The patients who sought first care from 302 formal healthcare providers had less diagnostic of delay 39 (IQR 23, 106) days than who got 303 304 care from informal providers 95 (IQR 51, 226) days. The patients with co-morbid disease had a median diagnostic delay of 67 (IQR 33, 98) days which was less than who didn't had co-305 morbid diseases 90 (IQR 37, 219) days. The median diagnostic delay of the patients who had 306 ≤3 initial symptoms was 80 (IQR 32.5, 174.5) days (Table 3). 307

The median treatment delay was found more among men (8 days), ≥55 years of age (8 days), rural people (8 days), not attend school (8 days), who had previous TB infections (8 days), and who is manual workers (8 days) or occupation was "Sales & Service" (8.5 days). However, the patients who first seek care from formal providers (5.5 days) and patients with co-morbid diseases (6 days) were found to have less median treatment delay (Table 3).

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

- The median total delay was found more among men (124 days), rural patients (108 days),
- Never married (141.5 days), housewives (134.5 days), manual workers (104 days), family
- income ≤10,000 BDT (129 days), patients who had pre-TB (119 days), number of care-seeking
- points more than 5 (176 days) and patients who had initial symptoms more than 3 (150 days).
- On the other side, the median total delay was comparatively less among ≥55 years of age (87
- days), urban patients (68 days), who had diabetes (63 days), who first seek care from formal
- providers (67.5 days) and who had co-morbid diseases (75 days) (Table 3).

320

321 **Table 3**: Socio-demographic characteristics and personal history of DR-TB patients

Characteristics	N (%)	Patient delay	Diagnosis delay	Treatment initiation delay	Total Delay
		Median d	lelay (IQR) in days*	Ľ.	
Sex					
Women	69 (75)	6 (3-10)	87 (39-224)	6 (4-9)	104 (48-241)
Men	23 (25)	14 (3-25)	102 (33-180)	8 (4-14)	124 (57.5-213.5)
Age (year)		• •			· · ·
16-34	45 (48.91)	7 (3-15)	101.5 (36-201)	7 (4-11)	119 (55-240)
35-54	23 (25.00)	6.5 (3-15)	96.5 (64-184)	7 (4-14)	115 (102-190)
≥55	24 (26.09)	5.5 (1.5-11)	64.5 (32-221.5)	8 (5-13.5)	87 (44-235.5)
Residence			<u>`</u>		, , , , , , , , , , , , , , , , , , , ,
Rural	66 (71.74)	7 (3-14)	90 (37-226)	8 (5-13)	108 (61-250)
Urban	22 (23.91)	7 (3-30)	60 (31-129)	6 (3.5-12)	68 (45-162)
Semi-urban	04 (4.35)	3 (1-6)	140.5(84.5-207.5)	4.5 (3.5-8)	149.5 (95-215.5)
Marital Status		× /			, ,
Ever married	76 (82.61)	7 (3-15)	84 (42-206.5)	7 (4-11)	106 (62-234.5)
Never married	16 (17.39)	5 (3-14.5)	125 (23.5-211.5)	8 (3.5-13.5)	141.5 (56-238.5)
Employment					
Unemployed	9 (9.78)	14 (3-15)	52 (37-201)	6 (4-8)	61 (55-241)
Sales & service	16 (17.39)	3.5 (3-7.5)	80 (24-222)	8.5 (4-12.5)	90 (42-236)
Business	10 (10.87)	7 (3-15)	64 (30-81)	7 (4-9)	91 (47-120)
Manual work	40 (43.48)	7 (3-10)	89.5 (60-224)	8 (4-17)	104 (78-240)
Housewife	9 (9.78)	7 (1.5-20)	106 (62-142)	6 (5-8)	134.5 (88.5-189.5)
Other	8 (8.70)	18 (6-30.5)	137 (56.5-255)	4 (3-8)	208.5 (68-296)
Educational status				()	
Not attended school	42 (45.65)	6 (2-14)	87 (45-219)	8 (5-13)	103 (66.5-241)
Primary	19 (20.65)	7 (3-15)	104 (60-222)	7 (3-13)	115 (81-162)
Secondary & above	31 (33.70)	7 (3-15)	81 (36-180)	7 (3-11)	102 (48-241)
Current smoker					
Yes	15 (16.30)	7 (4-15)	125 (60-237)	7.5 (5-11)	119 (78-255)
No	77 (83.70)	7 (3-14.5)	84 (36-194)	7 (4-13)	104 (55-229)
Past smoker				, <i>, , , , , , , , , , , , , , , , , , </i>	
Yes	47 (51.09)	7 (2-10)	91 (37-231)	8 (4-14)	103 (54.5-246)
No	45 (48.91)	7 (3-15)	85 (36-180)	7 (4-10.5)	111.5 (57.5-213.5)
Family income (BDT)		× /			
≤10000	32 (34.78)	7 (3-15)	103 (56-226)	7 (4-9)	129 (81-242)
10001-20000	38 (41.30)	7 (3-15)	60 (19-180)	8 (3.5-13)	82 (41-195)
≥20000	22 (23.91)	4 (3-7)	96 (62-194)	7 (5-14)	106.5 (69-
Consume alcohol		<u>* '</u> /			
Yes	6 (6.52)	3.5 (3-6)	258.5 (95-297)	7 (4-7)	236 (104-303)
No	86 (93.48)	7 (3-15)	81 (33-184)	7.5 (4-13)	108 (55-229)
DM					

T 7	16(15.00)	E (2, 5, 2, 0)	22 (22 (1)	5.5.(2.0)	(2, (22, 11, 5))
Yes	16 (17.39)	7 (3.5-20)	32 (23-64)	5.5 (3-9)	63 (33-115)
No	76 (82.61)	7 (3-15)	98 (60-222)	8 (4-13)	112 (78-241)
BCG scar					
Yes	60 (65.22)	7 (2-10)	80.5 (37-180)	7 (3-11)	102 (58-224)
No	21 (22.83)	7 (3-15)	97.5 (21-201.5)	7.5 (5.5-18.5)	112 (33-229)
Don't know	11 (11.96)		180 (60-295)	7.5 (4-12)	201.5 (93-291.5)
History of the previous TB					
Yes	62 (67.39)	7 (3-12)	105 (62-231)	8 (4.5-11)	119 (84-252)
No	30 (32.61)	7 (3-21)	39 (24-89)	6 (4-14)	64.5 (42.5-145)
Number of care- seeking points					
<u>≤4</u>	53 (57.61)	7 (3-15)	62 (30-134)	7 (4-10.5)	78 (47-150)
>4	39 (42.39)	7 (3-15)	142 (72-237)	8 (4-16)	176 (90-255)
Number of initial symptoms		· · · · · ·		<u> </u>	
≤3	67 (72.83)	7 (3-15)	80 (32.5-174.5)	8 (5-13)	108 (58-224)
>3	25 (27.17)	6 (3-10)	143.5(53.5-239.5)	7 (3.5-8.5)	150 (55-242)
Type of first healthcare provider					
Formal	17 (18.68)	8 (3-30)	39 (23-106)	5.5 (2.5-10.5)	67.5 (34-145)
Informal	74 (81.32)	7 (3-14)	95 (52-226)	8 (4-13.5)	109 (63-250)
Co-morbid disease					
Yes	10 (10.87)	4.5 (3-7)	67 (33-98)	6 (4-9)	75 (55-98)
No	82 (89.13)	7 (3-15)	90 (37-219)	7.5 (4-12.5)	111.5 (57.5-240.5)
Treatment registration group				· · ·	
New, MDR	25 (27.17)	7 (3-15)	36.5 (23-109)	5 (4-13)	57.5 (37.5-145)
Relapse, MDR	29 (31.52)	7 (3-10)	92.5 (30-238.5)	7.5 (4-11.5)	102 (47-255)
Re-treatment, MDR	33 (35.87)	5 (3-15)	105 (70-194)	8 (5.5-11)	119 (90-236)
Other, MDR	2 (2.17)	10.5 (7-14)	119 (37-201)	6.5 (4-9)	136 (48-224)
X-DR	3 (3.26)	21 (15-30)	81 (64-283)	19.5 (18-21)	215.5 (115-316)

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

322 In logistic regression analysis, the patient delay was found significantly associated with never

323 married (OR=4.57, 95 % Cl=1.20-17.33), non-diabetic (OR=3.19, 95 % Cl=1.01-10.10) (Table-

4). The diagnostic delay was significantly associated with the number of care-seeking points

325 more than 4 (OR=3.33, 95% CI= 1.38-8.03), non-diabetic (OR=10.16, 95% CI= 2.15-47.90). No

variable was found significantly associated with treatment delay. However, total delay was

significantly associated with being non-diabetic (OR=5.65, CI= 1.49-21.45), and the number

328 of care-seeking points was more than 4 (OR=3.79, 95% CI= 1.55-9.24).

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

330 Table 4: Logistic regression analysis of the determinants of the patient, diagnostic,

331 treatment, and total delay among the DR-TB patients

Variable	Categories	Patient included	Pati	ent delay	Diag	nostic delay	Treat	nent delay	Т	otal Delay
			OR	95% CI	OR	95% CI	OR	95% CI	O R	95% CI
Sex	Male	69	1		1		1		1	
	Female	23	0.71	0.27-1.02	1.34	0.52-3.46	0.44	0.17-1.14	1.1 2	0.44-2.89
Age (year)	16-34	45	1		1		1		1	
	35-54	22	0.87	0.32-2.43	1.53	0.54-4.37	0.96	0.34-2.67	0.8 8	0.31-2.45
	55 and above	25	1.31	0.49-3.54	0.49	0.18-1.34	1.70	0.61-4.74	0.3	0.12-0.96
Education	No education	44	1		1		1		1	
	Primary	19	0.82	0.30-2.41	1.11	0.38-3.26	0.46	0.15-1.39	0.9 0	0.31-2.74
	Secondary & above	29	1.49	0.57-3.88	1.07	0.42-2.74	0.64	0.24-1.66	1.0 7	0.42-2.74
Residence	Rural	66	1		1		1		1	
~ •	Urban	26	0.63	0.25-1.57	0.76	0.31-1.89	0.49	0.19-1.23	1	0.40-2.48
Smoke currently	Yes	15	1	0.25.2.10	1	0.20.2.72	1	0.12.1.77	1	0.52.1.55
•	No	77	1.05	0.35-3.18	0.90	0.30-2.72	0.46	0.13-1.57	0.6	0.53-4.21
Distance of near health	<5 km	59	1	0.0.1.1	1	0.61.2	1	0.00	1	0.000
facility	≥5 km	33	0.57	0.24-1.35	1.50	0.64-3.55	0.77	0.32-1.82	0.9	0.39-2.13
Diabetes	Yes	16	1 3.19*	1.01-	1 10.16*	2.15-47.90	1	0.94-8.71	1	1 40 21 4
	No	76	3.19*	1.01- 10.10	10.10*	2.15-47.90	2.86	0.94-8./1	5.6 5*	1.49-21.45
BCG scar	Yes	52	1		1		1		1	
	No	40	0.73	0.32-1.68	1.32	0.58-3.02	1.59	0.68-3.72	1.4 3	0.62-3.26
Pre-TB	Yes	62	1		1		1		1	
	No	30	0.63	0.26-1.52	0.27	0.11-0.69	0.39	0.16-0.96	0.3 6	0.15-0.90
Complete	Yes	25	1		1		1		1	
previous treatment	No	39	2.55	0.91-7.15	1.26	0.45-3.48	1.13	0.39-3.23	1.4 8	0.53-4.08
Number of care-seeking	Less than or equal to 4	36	1		1		1		1	
point	More than 4	56	0.92	0.40-2.14	3.33*	1.38-8.03	1.49	0.64-3.48	3.7 9*	1.55-9.24
Гуре оf	Formal	19	1		1		1		1	
provider at first point	Informal	73	1.09	0.39-3.00	2.08	0.73-5.88	1.78	0.65-4.94	1.1 4	0.41-3.14
Freatment	Primary	63	1		1		1		1	
registration group	Secondary	29	1.29	0.53-3.13	1.92	0.78-4.71	1.52	0.61-3.79	1.6 6	0.68-4.04
Marital	Ever married	76	1		1		1		1	0.55
status	Never married	16	4.57*	1.20- 17.33	1.29	0.43-3.81	1.21	0.40-3.68	2.5 8	0.82-8.13
Consume	Yes	7	1		1		1		1	
Alcohol	No	85	8.17	0.94- 70.83	0.16	0.02-1.35	1.07	0.23-5.09	0.3 7	0.07-2.03
Consume	Yes	4	1		1		1		1	
substances	No	88	3.77	0.377- 37.67	0.33	0.03-3.33	0.46	0.05-4.59	0.3 2	0.03-3.18
mprisonmen	Yes	12	1		1		1		1	
t Contact with	No Yes	80	0.83	0.24-2.84	1.55	0.45-5.29	1.02	0.30-3.48	1	0.30-3.36
	1 05	26	1	0.12.1.01	1 25	0.53-3.42	1 0.90	0.35-2.33	0.9	0.36-2.34
DR-TB	No	56	0.36	0.13-1.01	1.35	0.33-3.42	0.90	0.55-2.55	0.9	0.30-2.34

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

Asthma	Yes	10	1		1		1	0.25-3.59	1	
	No	82	1.21	0.33-4.52	1.65	0.43-6.30	0.94	0.25-3.59	2.5 7	0.62-10.65

332

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

334 Discussion

Healthcare-seeking patterns determine the progression, prognosis, and outcome of DR-TB 335 336 patients. Choice of healthcare has a key role in the journey to get a cure. The first care-337 seeking point is important as well as the number of providers. Bangladesh has a pluralistic health system where the coexistence of different stakeholders, including formal and 338 informal healthcare providers, is usual(29). The referral system is not well-established, 339 340 especially between informal to formal providers. This study revealed that most of the DR-TB patients (81.32%) were initially visited by informal providers, dominantly drug sellers 341 (68.48%). Other informal providers were village doctors, traditional healers, homeopaths, 342 ayurvedic, etc. Similar findings were found in other studies regarding care-seeking behaviors 343 of TB/MDR-TB patients in Bangladesh(14)(30). A study among TB patients in India, 344 Zimbabwe, and Ethiopia found that two-thirds of them sought first care from non-gualified 345 professionals(31)(32)(33). Informal care providers usually treat with medicine without 346 suggesting any investigations(15). Prescription of antibiotics irrationally is also common 347 among them(34). Also, they don't refer patients to formal providers or DOTS centers. So, a 348 large portion of the patients had more diagnostic delays found by this study. Patients seeking 349 initial care from informal providers were found to have more than twice the median 350 diagnostic delay, as those who seek care from formal providers. A previous study among TB 351 patients found more health system delays (52%) who seek care from informal providers than 352 353 formal providers (16%)(34). Policymakers should keep in mind this larger portion of the cakeinformal caregivers for effective control of DR-TB. Awareness programs should introduce, 354 train them, and establish a referral system between informal to formal caregivers to reduce 355 delays. 356

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

The study calculated the number of care-seeking points from the initial symptom of DR-TB 357 358 to confirmatory diagnosis. The median number of care-seeking points for DR-TB patients was found 5 which is more than in other countries like the USA-4, India-2, and Zimbabwe-3 359 (35) (33) (32). Care seekers from informal providers had more care-seeking points before 360 diagnosis. More care-seeking points cause more diagnostic and health system delays. 361 Ultimately, these phenomena cause a longer period of DR-TB transmission in the 362 communities. Preventing this vicious cycle is of utmost need to control DR-TB in low-363 364 resource countries like Bangladesh.

The median time between the onset of the first symptom of DR-TB and the first care-seeking 365 was found 7 days in this study, which is the patient delay. No other study in Bangladesh 366 calculated the patient delays among DR-TB patients. However, studies from other countries 367 368 found more median patient delays among DR-TB/uncomplicated TB patients such as Zimbabwe- 26 days, Ethiopia- 35 days, China- 58 days (95% of cases), USA- 25 days, and 369 India- 15 days(33)(31)(6)(36)(37). One of the reasons for the low patient delay found in our 370 study is the operational definition. This study defined 'patient delay' as the time between the 371 appearance of the first symptom to the first consultation with healthcare providers 372 irrespective of their types- formal or informal, whether most of the study considered only 373 formal providers(38). The healthcare system of many countries is not as pluralistic as 374 375 Bangladesh. Seeking care from drug sellers is common in Bangladesh as there is no strict monitoring system though there is a provision of not selling drugs without the prescription 376 of qualified professionals. Two out of five people in Dhaka the capital city of Bangladesh seek 377 care from community pharmacies(39). From the patient perspective, at the community level, 378 pharmacies/informal providers are nearer, less time-consuming, and more cost-effective 379 than formal healthcare settings. 380

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

381 We found a median diagnostic delay of 88 days among the study participants. A previous 382 study (2012-13) in Bangladesh among MDR-TB patients found a health system delay of 7.1 383 weeks while the provider's delay was only 4 weeks which is much lesser than the findings of this study(10). There was a possible role of informal providers for this variation. Very few 384 participants (10.8%) in that study sought initial care from informal providers compared to the 385 findings of our study (81.32%). Female participants (75% vs 33.3%), Rural participants (71.74%) 386 vs 49.3%), and illiterates (45.65% vs 22%) were more in our study than Rifat et al. Moreover, 387 388 27.17% of the participants of this study were categorized as new MDR-TB while the previous 389 study had only 2.4 %(40). The median diagnostic delay among MDR-TB patients in China was 84 days while in Zimbabwe 97 days(41)(6)(33) which was very similar. A previous study 390 among TB patients found a diagnostic delay of 68.5 days in Bangladesh which is less than our 391 392 study(15). Seeking care from informal providers at the first point, seeking care from multiple healthcare providers, or the tendency to switch providers several times contributes to 393 diagnostic delay. On top of that, gualified healthcare providers occasionally didn't suggest 394 395 investigations necessary for diagnosing DR-TB(11). The diagnostic delay is a key indicator of the health system. Reducing diagnostic delays through strengthening a pluralistic health 396 system is a challenge for Bangladesh. 397

This study found a median treatment initiation delay of 7 days. The median treatment initiation delays found previous studies was 9 days in China(42), 8 days in Gujrat, India(43) 13 days in Myanmar(44), 10 days in Bangladesh(21), 10-22 days in South Africa(45), 9-17 days in Russia(46), 7 days in Bhopal, India(47). The treatment initiation delays mostly occur due to repetition of confirmatory tests, baseline investigations before starting treatment, and sometimes an inadequate number of resident beds for DR-TB in tertiary hospitals(21). Also, the patient's seriousness about the disease due to lack of awareness and motivation is

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

another possible cause of delay(48). Treatment delay results in poor prognosis and risk of
transmission of DR-TB bacilli to the community. However, the treatment initiation delays
can be reduced by ensuring an adequate number of beds for DR-TB in all tertiary hospitals,
ensuring proper counseling after diagnosis, and suggesting baseline investigations after
admission of DR-TB patients into hospitals.

410 The median total delay was 108.5 days in this study. Previous studies found the median diagnostic delay of 57 days in the USA(36), 120 days in China, 100 days in Pakistan(27), and 411 132 days in Zimbabwe. Rifat et al found a median of 7.1 weeks of health system delay among 412 MDR-TB patients in Bangladesh in 2015(21). Another study among TB patients in Bangladesh 413 found a total delay of 12 weeks(34). The patient delays, diagnostic delays, and treatment 414 delays contribute to the length of total delays. Both patients and health systems are 415 responsible for long total delays. During these delays, resistant tuberculosis bacilli are 416 continuously spread from person to person. The patient's lung condition can worsen during 417 this period. Thus, the prognosis of the disease becomes poor which contributes to treatment 418 failure, higher mortality, and economic loss. The chance of fatality is very high in case of a 419 long total delay(21). 420

Being non-diabetic was significantly associated with patient, diagnostic, and total delays. In 421 Bangladesh, most (over 50%) diabetic patients are registered with Bangladesh Diabetic 422 Somity (BADAS) and seek care (95.2%) from private facilities of BADAS while only 4.3% seek 423 care from informal providers(49). This scenario can clarify why diabetic patients had fewer 424 delays than non-diabetics in Bangladesh. The patient's delay was significantly associated 425 with never being married in this study. Unmarried people may have a lack of self-motivation 426 and social support, this may be the possible reason for more patient delays among them (50). 427 The number of care-seeking points more than 4 was found significantly associated with 428

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

diagnostic and total delays. This is obvious that more care-seeking points will contribute to

430 more delays.

The strength of the study is that the investigators interviewed patients face to face. Thus, 431 the information regarding different delays could easily validate with the patient's memory 432 and record files. DR-TB patients are not available in abundance in the hospitals due to the 433 low case detection rate in Bangladesh(51)(52). The study covered both rural and urban 434 populations as well as non-government and government TB hospitals within certain 435 geographic regions. There is also a possibility of recall bias regarding the patient delays and 436 healthcare-seeking behavior, as researchers needed to rely on the patient's memory. 437 However, most of the respondents were drawn from the intensive phase of treatment, so the 438 recall period was lesser than community patients. Sometimes few medical records were 439 found missing thus it was difficult to identify the date of diagnosis or treatment initiation. 440 However, researchers had made an effort to minimize the discrepancies by checking all 441 medical records available to patients and service records of hospitals. Few data regarding 442 delays were missing as some patients could not remember the date of their first care-443 seeking. So, calculation of total delays also was not possible for those patients. This missing 444 445 data on patient delay did not affect the overall outcome of the study.

446 **Conclusion**

Most of the DR-TB patients sought initial healthcare from informal providers while most of the patients seek care from more than five care-seeking points leading to more patient and diagnostic delays. Patient, diagnostic, and treatment initiation delays among the patients were more than recommended resulting in the transmission of the drug-resistant bacilli in the community and increasing the burden of the disease. Community-based interventions are necessary to ensure needful healthcare from formal providers and to reduce the number

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

453	of care-seeking points before diagnosis. Appropriate training and awareness among
454	healthcare providers could reduce diagnostic delays. This study also recommends ensuring
455	the availability of the Rapid diagnostic test e.g., GeneXpert in primary health care centers.
456	The evidence could help the policymakers, public health specialists, and healthcare providers
457	to improve the TB control program, ensure mass awareness to reduce patient delay,
458	strengthen the health system to reduce diagnostic delay, and ensure early admission to
459	reduce the treatment delay with a vision to the successful implementation of the "END TB
460	2030" strategy.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

462 References

463	1.	WHO. GLOBAL TUBERCULOSIS REPORT 2021 [Internet]. Available from	1:
-----	----	---	----

- 464 http://apps.who.int/bookorders. [cited 2022 Nov 22]
- 465 2. Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-
- 466 resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis
- 467 treatment in East Shoa, Ethiopia. BMC Public Health. 2018 Apr 2;18(1).
- 468 3. WHO. THE END-TB STRATEGY. 2015; [Internet]. Available from:
- 469 https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19. [cited 2022 Nov
- 470 22]
- 471 4. Kidenya BR, Mshana SE, Fitzgerald DW, Ocheretina O. Genotypic drug resistance
- 472 using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates
- 473 from North-western Tanzania. Tuberculosis. 2018;
- 474 5. Trauner A, Borrell S, Reither K, Gagneux S. Evolution of drug resistance in
- 475 tuberculosis: Recent progress and implications for diagnosis and therapy. Drugs.
- 476 2014;
- 477 6. Cheng S, Chen W, Yang Y, Chu P, Liu X, Zhao M, et al. Effect of Diagnostic and
- 478 Treatment Delay on the Risk of Tuberculosis Transmission in Shenzhen, China: An
- 479 Observational Cohort Study, 1993-2010. PLoS ONE. 2013 Jun 27;8(6).
- 480 7. WHO. Rapid Communication: Key changes to the treatment of drug-resistant
- 481 tuberculosis. World Health Organization [Internet]. 2022;(WHO/UCN/TB/2022.2.):6.
- 482 Available from:

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

483 https://apps.who.int/iris/handle/10665/275383%0Ahttp://apps.who.int/bookorders.

484 [cited 2022 Nov 22]

- 485 8. Van Cutsem G, Isaakidis P, Farley J, Nardell E, Volchenkov G, Cox H. Infection
- 486 Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key.
- 487 Clinical Infectious Diseases. 2016;62(Suppl 3):S238–43.
- 488 9. WHO. Global tuberculosis report 2018. 2018. 265 p. Available
- 489 from: https://apps.who.int/iris/handle/10665/274453. [cited 2022 Nov 22]
- 490 10. Rifat M, Hall J, Oldmeadow C, Husain A, Hinderaker SG, Milton AH. Factors related
- 491 to previous tuberculosis treatment of patients with multidrugresistant tuberculosis in
- 492 Bangladesh. BMJ Open. 2015;
- 493 11. Farah MG, Rygh JH, Steen TW, Selmer R, Heldal E, Bjune G. Patient and health care

494 system delays in the start of tuberculosis treatment in Norway. BMC Infectious
495 Diseases. 2006 Feb 24;6.

496 12. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-

497 prescription antimicrobial use worldwide: A systematic review. The Lancet Infectious
498 Diseases. 2011.

499 13. Sidharta SD, Yin JDC, Yoong JSY, Khan MS. High use of private providers for first

500 healthcare seeking by drug-resistant tuberculosis patients: A cross-sectional study in

501 Yangon, Myanmar. BMC Health Services Research. 2018 Apr 11;18(1).

Hossain S, Zaman K, Quaiyum A, Banu S, Husain A, Islam A, et al. Care seeking in
 tuberculosis: Results from a countrywide cluster randomised survey in Bangladesh.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

504 BMJ Open. 2014;4(5).

505	15.	Ehsanul Huq KATM, Moriyama M, Zaman K, Chisti MJ, Long J, Islam A, et al. Health
506		seeking behaviour and delayed management of tuberculosis patients in rural
507		Bangladesh 11 Medical and Health Sciences 1117 Public Health and Health Services.
508		BMC Infectious Diseases. 2018 Oct 12;18(1).
509	16.	Law S, Piatek AS, Vincent C, Oxlade O, Menzies D. Emergence of drug resistance in
510		patients with tuberculosis cared for by the Indian health-care system: a dynamic
511		modelling study. The Lancet Public Health. 2017;
512	17.	Megerso A, Deyessa N, Jarso G, Worku A. Lived experiences of tuberculosis patients
513		and their implications for early tuberculosis case identification and management in
514		pastoralist community setting: A qualitative study in Borena zone, Oromia region of
515		Ethiopia. BMC Health Services Research. 2020 Oct 9;20(1).
516	18.	Atre SR, Mistry NF. Multidrug-resistant tuberculosis (MDR-TB) in India: An attempt
517		to link biosocial determinants. Vol. 26, Journal of Public Health Policy. 2005. p. 96–
518		114.
519	19.	Sullivan BJ, Esmaili BE, Cunningham CK. Barriers to initiating tuberculosis treatment
520		in sub-Saharan Africa: A systematic review focused on children and youth. Vol. 10,
521		Global Health Action. Taylor and Francis Ltd.; 2017.
522	20.	Mistry N, Rangan S, Dholakia Y, Lobo E, Shah S, Patil A. Durations and delays in care
523		seeking, diagnosis and treatment initiation in uncomplicated pulmonary
524		Tuberculosis patients in Mumbai, India. PLoS ONE. 2016 Mar 1;11(3).

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

525 21. Rifat M, Hall J, Oldmeadow C, Husain A, Milton AH. Health system delay in

- 526 treatment of multidrug resistant tuberculosis patients in Bangladesh. BMC Infectious
- 527 Diseases. 2015 Nov 16;15(1).
- 528 22. WHO 2009. Global tuberculosis control: a short update to the 2009 report. World
- 529 Health Organization. 2009; Available from:
- 530 https://apps.who.int/iris/handle/10665/44241 [cited 2022 Nov 22]
- 531 23. Pirkis JE, Speed BR, Yung AR, Dunt DR, Macintyre CR, Plant AJ. Time to initiation of
- anti-tuberculosis treatment. Vol. 77, Tubercle and Lung Disease. 1996.
- 533 24. National Tuberculosis Control Programme. National Guidelines and Operational
- 534 Manual for Programmatic Management of Drug Resistant TB [Internet]. 2020 [cited
- 535 2022 Jun 6]. Available from: https://www.ntp.gov.bd/guidelines/
- 536 25. Banu S, Mahmud AM, Rahman MT, Hossain A, Uddin MKM, Ahmed T, et al.
- 537 Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of
- 538 Bangladesh. PLoS ONE. 2012;7(7).
- 539 26. Damien Foundation. Annual Report 2017 [Internet]. 2017 [cited 2022 Sep 1].
- 540 Available from: www.damienfoundation-bd.com
- 541 27. World Health Organization. Diagnostic and treatment delay in tuberculosis. World
- 542 Health Organization. 2006; Available from:
- 543 https://apps.who.int/iris/handle/10665/116501 [cited 2022 Nov 22]
- 544 28. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and
- 545 treatment of tuberculosis. Vol. 8, BMC Public Health. BioMed Central Ltd.; 2008.

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

- 546 29. Ahmed SM. Exploring health-seeking behaviour of disadvantaged populations in
- 547 rural Bangladesh. Karolinska University Press. 2005.
- 548 30. Ahmed SM. Exploring health-seeking behaviour of disadvantaged populations in
- 549 rural Bangladesh. Karolinska Institutet; 2005.
- 550 31. Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-
- 551 resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis
- 552 treatment in East Shoa ,. 2018;1–6.
- 553 32. Kapoor SK, Raman AV, Sachdeva KS, Satyanarayana S. How did the TB patients
- reach DOTS services in Delhi? a study of patient treatment seeking behavior. PLoS
- 555 ONE. 2012 Aug 6;7(8).
- 556 33. Tadokera R, Huo S, Theron G, Timire C, Manyau-Makumbirofa S, Metcalfe JZ. Health
- 557 care seeking patterns of rifampicin-resistant tuberculosis patients in Harare,
- 558 Zimbabwe: A prospective cohort study. PLoS ONE. 2021 Jul 1;16(7 July).
- 559 34. Sizear MMI, Nababan HY, Siddique MK Bin, Islam S, Paul S, Paul AK, et al.
- 560 Perceptions of appropriate treatment among the informal allopathic providers:
- 561 Insights from a qualitative study in two peri-urban areas in Bangladesh. BMC Health
- 562 Services Research. 2019 Jun 26;19(1).
- 35. Almeida CPB de, Skupien EC, Silva DR. Health care seeking behavior and patient
 delay in tuberculosis diagnosis. Cadernos de Saúde Pública. 2015;
- Sherman LF, Fujiwara PI, Cook + S V, Bazerman LB, Frieden TR. Patient and health
 care system delays in the diagnosis and treatment of tuberculosis. Vol. 3, INT J

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

567 TUBERC LUNG DIS. 1999.

568	37.	Mistry N, Rangan S, Dholakia Y, Lobo E, Shah S. Durations and Delays in Care
569		Seeking , Diagnosis and Treatment Initiation in Uncomplicated Pulmonary
570		Tuberculosis Patients in Mumbai , India. 2016;1–17.
571	38.	Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and
572		treatment of tuberculosis. BMC Public Health. 2008.
573	39.	Chowdhury F, Sturm-Ramirez K, Mamun A Al, Iuliano AD, Chisti MJ, Ahmed M, et al.
574		Effectiveness of an educational intervention to improve antibiotic dispensing
575		practices for acute respiratory illness among drug sellers in pharmacies, a pilot study
576		in Bangladesh. BMC Health Services Research. 2018 Aug 31;18(1).
577	40.	Rifat M, Hall J, Oldmeadow C, Husain A, Hinderaker SG, Milton AH. Factors related
578		to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis
579		in Bangladesh. Available from: http://dx.doi.org/10.1136/bmjopen-2015-008273
580	41.	Zhang X, Yin J, Li H, Li S, Walley J, Zou G, et al. Diagnostic and treatment delays of
581		multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study.
582		Tropical Medicine and International Health. 2015;20(11):1431–7.
583	42.	Zhang X, Yin J, Li H, Li S, Walley J, Zou G, et al. Diagnostic and treatment delays of
584		multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study.
585		Tropical Medicine and International Health. 2015;20(11):1431–7.
586	43.	Shewade HD, Shringarpure KS, Parmar M, Patel N, Kuriya S, Shihora S, et al. Delay
587		and attrition before treatment initiation among MDR-TB patients in five districts of

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh


588 Gujarat, India. Public Health Action. 2019 Feb 5;8(2):59–65.

589	44.	Htun YM, Khaing TMM, Yin Y, Myint Z, Aung ST, Hlaing TM, et al. Delay in diagnosis
590		and treatment among adult multidrug resistant tuberculosis patients in Yangon
591		Regional Tuberculosis Center, Myanmar: a cross-sectional study. BMC health
592		services research. 2018;
593	45.	Cox H, Dickson-Hall L, Ndjeka N, van't Hoog A, Grant A, Cobelens F, et al. Delays and
594		loss to follow-up before treatment of drug-resistant tuberculosis following
595		implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
596		PLoS Medicine. 2017;
597	46.	P. E, G. B, E. N, A. G, E. B, D. E, et al. The impact of a line probe assay based
598		diagnostic algorithm on time to treatment initiation and treatment outcomes for
599		multidrug resistant TB patients in Arkhangelsk Region, Russia. PLoS ONE. 2016;
600	47.	Shewade HD, Shringarpure KS, Parmar M, Patel N, Kuriya S, Shihora S, et al. Delay
601		and attrition before treatment initiation among MDR-TB patients in five districts of
602		Gujarat, India. Public Health in Action. 2018;
603	48.	Nigam S, Sharma RK, Yadav R, Rao VG, Mishra P, Lingala MA, et al. Experiences and
604		needs of patients with MDR/XDR-TB: A qualitative study among Saharia tribe in
605		Madhya Pradesh, Central India. BMJ Open. 2021 Aug 12;11(8).
606	49.	Bhowmik B, Siddiquee T, Ahmed T, Afsana F, Samad MA, Pathan F, et al. Diabetes
607		Care During 50 Years of Bangladesh. Bangladesh J Diabetol [Internet]. 2021;12:383-
608		90. Available from: http://www.journalofdiabetology.org


Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

609	50.	Wang W, Wang F, Peng Y, Liu K, Chen X, Chai C, et al. Factors associated with
-----	-----	---


- 610 health-seeking preference among people who were supposed to cough for more
- 611 than 2 weeks: A cross-sectional study in Southeast China. Patient Preference and
- 612 Adherence. 2020;14:1173–83.
- 613 51. WHO. REPORT: Global Tuberculosis Report 2013. Geneva: World Health
- 614 Organization. 2013. Available from: https://apps.who.int/iris/handle/10665/91355.
- 615 [cited 2022 Nov 22]
- 52. WHO. TUBERCULOSIS GLOBAL REPORT 2018. Geneva: World Health Organization;
- 617 2018. Available from: <u>https://apps.who.int/iris/handle/10665/274453</u>. [cited 2022 Nov
- 618 22]



Map of study site locations presenting the distribution of differe



Definition of different delays



Median and IQR of Different delays among